OABI (OmniAb) Tariff Resilience Score: 5/10 (As of Jul. 08, 2026)


OABI OmniAb Inc OABI
72 GF Score
Price $2.31
GF Value $2.27
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is OmniAb Tariff Resilience Score?

OmniAb OABI -0.86% 72 Tariff Resilience Score is 5 as of Jul. 08, 2026. GuruFocus rates OABI with a GF Score™ of 72/100 and a GF Value™ of $2.27 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,367 Biotechnology companies, OmniAb ranks better than 62.4% on this metric.

OmniAb has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

OmniAb has OmniAb Inc's reliance on global biotech supply chains exposes it to tariff risks. While it has some pricing power, its international dependencies make it moderately vulnerable.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes OmniAb might have Average Resilient.

OmniAb  (NAS:OABI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

OmniAb Tariff Resilience Score Related Terms

OABI vs VNDA, AVIR, UPB: Tariff Resilience Score Comparison

For the Biotechnology subindustry, OmniAb's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OmniAb Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where OmniAb's Tariff Resilience Score falls into.


OABI
72GF Score
OmniAb Inc OABI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
OmniAb (OABI) has a Tariff Resilience Score of 5 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, OmniAb ranks #514 out of 1367 companies in the Biotechnology industry, placing it in the top 37.6%.
Is OmniAb's Tariff Resilience Score too high?
OmniAb's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. OmniAb's value of 5 is 25% above this industry median. Based on the distribution chart, OmniAb ranks #514 out of 1367 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OmniAb has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OmniAb's Tariff Resilience Score compare to VNDA and AVIR?
According to the Biotechnology industry distribution chart, OmniAb ranks #514 out of 1367 companies for Tariff Resilience Score. This puts OmniAb in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. OmniAb's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OmniAb's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OmniAb's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OmniAb stock overvalued right now?
Based on GuruFocus' analysis, OmniAb (OABI) is currently considered Fairly Valued. The stock's GF Value™ is $2.27, compared to a current price of $2.31 — trading 1.5% above its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. OmniAb's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For OmniAb (OABI), the current Tariff Resilience Score is 5 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OmniAb (OABI) Overvalued in 2026?

Based on GuruFocus' analysis, OmniAb stock appears to be overvalued. The current stock price of $2.31 is trading 1.5% above its estimated GF Value™ of $2.27. GuruFocus considers OmniAb to be Fairly Valued.

Key valuation signals for OABI:

  • Tariff Resilience Score: 5
  • GF Value™: $2.27 vs. price of $2.31 (1.5% above fair value)
  • GF Score™: 72/100 with 3 warning signs
  • Industry Position: 25% above the Biotechnology median (#514 of 1367)

No single metric tells the full story. See the OABI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OmniAb Business Description

Address 5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
72GF Score

Get the complete analysis for OABI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.31
Price
$2.27
GF Value